Menu
Search
|

Menu

Close
X

Zafgen Inc ZFGN.OQ (NASDAQ Stock Exchange Global Select Market)

7.82 USD
+0.05 (+0.64%)
As of Feb 21
chart
Previous Close 7.77
Open 7.82
Volume 41,103
3m Avg Volume 39,649
Today’s High 8.31
Today’s Low 7.80
52 Week High 9.26
52 Week Low 3.21
Shares Outstanding (mil) 27.49
Market Capitalization (mil) 213.59
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.75 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-1.421
FY16
-2.121
FY15
-2.767
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
--
8.67
Price to Book (MRQ)
vs sector
2.39
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
1.42
15.38
LT Debt to Equity (MRQ)
vs sector
0.00
12.01
Return on Investment (TTM)
vs sector
-44.77
13.57
Return on Equity (TTM)
vs sector
-45.01
15.19

EXECUTIVE LEADERSHIP

Peter Barrett
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Thomas Hughes
President, Chief Scientific Officer, Director, Since 2017
Salary: $450,000.00
Bonus: --
Jeffrey Hatfield
Chief Executive Officer, Director, Since 2017
Salary: --
Bonus: --
Patricia Allen
Chief Financial Officer, Since 2013
Salary: --
Bonus: --
Dennis Kim
Chief Medical Officer, Since 2011
Salary: $367,500.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

175 Portland St Fl 4
BOSTON   MA   02114-1713

Phone: +1617.6224003

Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

SPONSORED STORIES